Pfizer withdraws application for Macugen indication

Pfizer Ltd has withdrawn an application from the European Medicines Agency to extend the indication of its eye medicine, Macugen (pegaptanib sodium) to include the treatment of visual impairment due to diabetic macular oedema, the EMA said.